Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Ixazomib

FDA approved · Rx

Oral proteasome inhibitor

Also known as: Ninlaro, MLN2238, MLN-2238, MLN 2238, MLN-9708 FREE BASE, ixazomibum

Evidence score

95/ 100

Strong evidence

Strong, human-grade evidence

Regulatory standing. FDA-approved prescription medicine
Human trials. Backed by controlled human studies
Registered human trials. 164 registered studies on ClinicalTrials.gov, most advanced Phase 4
2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Ixazomib, sold as Ninlaro, is an oral boronic acid based dipeptide that reversibly inhibits the proteasome, the cell machinery that breaks down unneeded proteins. Blocking the proteasome causes damaging proteins to build up in cancer cells, particularly myeloma cells, which can lead to their death.

What the evidence shows

Automatic summaryHuman trials

Ixazomib is FDA approved for use in combination with lenalidomide and dexamethasone to treat multiple myeloma in adults who have received at least one prior therapy. It has been studied in 163 registered human trials up to Phase 4, and uses outside its approved indication remain investigational.